#methylphenidate — Public Fediverse posts

DATE: August 13, 2026 at 12:00PM
SOURCE: PSYPOST.ORG

** Research quality varies widely from fantastic to small exploratory studies. Please check research methods when conclusions are very important to you. **
-------------------------------------------------

TITLE: Predictive single-dose test could guide ADHD treatment in adults

URL: https://www.psypost.org/predictive-single-dose-test-could-guide-adhd-treatment-in-adults/

Testing how a person responds to a single dose of stimulant medication might help doctors predict how well the treatment will work for them two months later. Researchers found that early changes in specific symptom scores accurately forecast long-term medication success in adults with attention-deficit/hyperactivity disorder. The study was published in the journal Translational Psychiatry.

Attention-deficit/hyperactivity disorder, commonly known as ADHD, is a neurodevelopmental condition characterized by varying levels of inattention, hyperactivity, and impulsivity. Stimulant medications, such as methylphenidate, represent the primary pharmacological treatment for the condition. These drugs help regulate attention and behavior by enhancing the availability of dopamine and noradrenaline in the brain. This mechanism reduces background noise in neural circuits, enabling patients to better maintain focus and control impulsive behaviors.

While stimulants reduce symptoms across large populations, individual patient responses vary widely. In standard clinical practice, doctors often prescribe these medications using a trial-and-error approach. Patients take a drug for weeks or months to see if it works and whether it causes intolerable side effects. If a medication fails, the patient must slowly taper off and try another option. This process can delay relief and prolong the academic, professional, and personal challenges patients face in their daily lives.

To bypass this waiting period, researchers have been searching for ways to predict treatment success before a patient commits to a long-term prescription. Previous investigations hinted that measuring brain activity after just one dose of medication could indicate its long-term effectiveness.

A research team led by Valeria Parlatini, a clinical academic at the University of Southampton and King’s College London, wanted to know if this predictive capability also applied to simpler, more accessible clinical tests. They designed a study to see if standard symptom questionnaires and computer-based behavioral assessments could forecast longer-term treatment outcomes.

The research team recruited 60 adult males diagnosed with ADHD. At the beginning of the study, each participant attended two testing sessions. In one session, they received a single 20-milligram dose of methylphenidate. In the other session, they received a placebo capsule. Participants did not know which pill they were taking on which day, ensuring their expectations did not influence their performance.

During both sessions, the researchers evaluated the participants using two tools about an hour after they took the pill, allowing the medication time to enter their bloodstream. The first tool was a self-report questionnaire called the Barkley Adult ADHD Rating Scale, which measures inattention and hyperactivity. The second was the Quantitative behavior test. This computer-based assessment tracks head movement with an infrared camera while the user completes a repetitive visual task, yielding objective scores for activity, impulsivity, and inattention.

After completing these initial tests, the participants began a standard daily regimen of long-acting methylphenidate. Following two months of this daily treatment, the researchers evaluated the participants again using the same questionnaire and computer test. They wanted to see if the behavioral changes recorded under the single initial dose aligned with the improvements observed at the two-month mark.

The researchers first analyzed individual scores from the initial tests against the long-term results. Out of the original group, 45 participants completed the questionnaire during the single-dose phase. The data showed that early reductions in self-reported hyperactivity and impulsivity after a single dose corresponded with improvements in those exact areas two months later.

However, changes in self-reported inattention under the single dose did not consistently predict long-term improvements in attention. This suggests that certain symptom domains are harder for patients to subjectively evaluate in the short term.

Conversely, early changes in all three main scores on the computer-based behavior test mapped onto longer-term improvements. Participants who demonstrated better objective focus and less movement under the single dose were highly likely to show those same benefits after two months of daily medication.

Next, the team used a machine learning technique known as Lasso regression to build predictive models. This specific algorithm automatically selects a limited set of the strongest predictive variables from a large pool of data, ignoring weaker factors to prevent the model from becoming overly complicated. This analysis combined the single-dose test results with baseline demographic and clinical traits. These baseline traits included age, intelligence quotient, years of education, and initial symptom severity.

These combined models successfully predicted actual patient outcomes at the two-month follow-up for most of the tested measures. The models accurately forecast total symptom improvement, changes in hyperactivity, and shifts in computer-tracked impulsivity and inattention. The researchers noted that combining the single-dose response with baseline traits like intelligence and age improved the accuracy of the predictions beyond using the single-dose data alone.

In a secondary analysis, the researchers looked closer at how different types of intelligence related to treatment outcomes. They found that visual-spatial problem-solving skills were linked to long-term improvements in attention. Meanwhile, verbal intelligence scores were associated with long-term reductions in hyperactivity and impulsivity. The study also found that older participants tended to see better improvements in impulsivity, while younger participants saw greater gains in attention.

The study evaluated a specific demographic group, which shapes how the results apply to the broader population. The researchers exclusively enrolled adult men to limit potential biological variables in a related brain imaging analysis. As a result, the findings require validation in women and people of other genders to confirm whether the predictive tests work universally.

Additionally, the participants had no co-occurring mental health or developmental conditions, such as autism. People with ADHD frequently have other diagnoses, which can alter how they respond to stimulant medications. Testing these predictive models in a more diverse patient group will help determine their utility in everyday medical settings.

The models also need to be tested on entirely separate groups of patients. While the machine learning algorithms performed well on the data they were trained on, predictive tools often require external validation to ensure they do not just reflect the specific characteristics of the original sample.

The single-dose prediction approach remains in the testing phase and is not yet a replacement for standard clinical monitoring. In the future, researchers hope to incorporate physiological measures, such as heart rate variability, to build even more accurate predictive profiles. Combining objective computer tests, questionnaires, and biological markers could eventually help doctors tailor prescriptions to individual patients from day one.

The study, “Clinical response to a single-dose methylphenidate challenge is indicative of treatment response at two months in adults with ADHD,” was authored by Valeria Parlatini, Joaquim Radua, Hannah Thomas, Miguel Garcia-Argibay, Alessio Bellato, Samuele Cortese, and Declan Murphy.

URL: https://www.psypost.org/predictive-single-dose-test-could-guide-adhd-treatment-in-adults/

-------------------------------------------------

Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org

Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot

-------------------------------------------------

#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #ADHD #methylphenidate #single-doseprediction #adult ADHD #stimulantresponse #predictivepsychology #behavioralassessment #machinelearning #TranslationalPsychiatry #personalizedmedicine

DATE: August 13, 2026 at 12:00PM
SOURCE: PSYPOST.ORG

** Research quality varies widely from fantastic to small exploratory studies. Please check research methods when conclusions are very important to you. **
-------------------------------------------------

TITLE: Predictive single-dose test could guide ADHD treatment in adults

URL: https://www.psypost.org/predictive-single-dose-test-could-guide-adhd-treatment-in-adults/

Testing how a person responds to a single dose of stimulant medication might help doctors predict how well the treatment will work for them two months later. Researchers found that early changes in specific symptom scores accurately forecast long-term medication success in adults with attention-deficit/hyperactivity disorder. The study was published in the journal Translational Psychiatry.

Attention-deficit/hyperactivity disorder, commonly known as ADHD, is a neurodevelopmental condition characterized by varying levels of inattention, hyperactivity, and impulsivity. Stimulant medications, such as methylphenidate, represent the primary pharmacological treatment for the condition. These drugs help regulate attention and behavior by enhancing the availability of dopamine and noradrenaline in the brain. This mechanism reduces background noise in neural circuits, enabling patients to better maintain focus and control impulsive behaviors.

While stimulants reduce symptoms across large populations, individual patient responses vary widely. In standard clinical practice, doctors often prescribe these medications using a trial-and-error approach. Patients take a drug for weeks or months to see if it works and whether it causes intolerable side effects. If a medication fails, the patient must slowly taper off and try another option. This process can delay relief and prolong the academic, professional, and personal challenges patients face in their daily lives.

To bypass this waiting period, researchers have been searching for ways to predict treatment success before a patient commits to a long-term prescription. Previous investigations hinted that measuring brain activity after just one dose of medication could indicate its long-term effectiveness.

A research team led by Valeria Parlatini, a clinical academic at the University of Southampton and King’s College London, wanted to know if this predictive capability also applied to simpler, more accessible clinical tests. They designed a study to see if standard symptom questionnaires and computer-based behavioral assessments could forecast longer-term treatment outcomes.

The research team recruited 60 adult males diagnosed with ADHD. At the beginning of the study, each participant attended two testing sessions. In one session, they received a single 20-milligram dose of methylphenidate. In the other session, they received a placebo capsule. Participants did not know which pill they were taking on which day, ensuring their expectations did not influence their performance.

During both sessions, the researchers evaluated the participants using two tools about an hour after they took the pill, allowing the medication time to enter their bloodstream. The first tool was a self-report questionnaire called the Barkley Adult ADHD Rating Scale, which measures inattention and hyperactivity. The second was the Quantitative behavior test. This computer-based assessment tracks head movement with an infrared camera while the user completes a repetitive visual task, yielding objective scores for activity, impulsivity, and inattention.

After completing these initial tests, the participants began a standard daily regimen of long-acting methylphenidate. Following two months of this daily treatment, the researchers evaluated the participants again using the same questionnaire and computer test. They wanted to see if the behavioral changes recorded under the single initial dose aligned with the improvements observed at the two-month mark.

The researchers first analyzed individual scores from the initial tests against the long-term results. Out of the original group, 45 participants completed the questionnaire during the single-dose phase. The data showed that early reductions in self-reported hyperactivity and impulsivity after a single dose corresponded with improvements in those exact areas two months later.

However, changes in self-reported inattention under the single dose did not consistently predict long-term improvements in attention. This suggests that certain symptom domains are harder for patients to subjectively evaluate in the short term.

Conversely, early changes in all three main scores on the computer-based behavior test mapped onto longer-term improvements. Participants who demonstrated better objective focus and less movement under the single dose were highly likely to show those same benefits after two months of daily medication.

Next, the team used a machine learning technique known as Lasso regression to build predictive models. This specific algorithm automatically selects a limited set of the strongest predictive variables from a large pool of data, ignoring weaker factors to prevent the model from becoming overly complicated. This analysis combined the single-dose test results with baseline demographic and clinical traits. These baseline traits included age, intelligence quotient, years of education, and initial symptom severity.

These combined models successfully predicted actual patient outcomes at the two-month follow-up for most of the tested measures. The models accurately forecast total symptom improvement, changes in hyperactivity, and shifts in computer-tracked impulsivity and inattention. The researchers noted that combining the single-dose response with baseline traits like intelligence and age improved the accuracy of the predictions beyond using the single-dose data alone.

In a secondary analysis, the researchers looked closer at how different types of intelligence related to treatment outcomes. They found that visual-spatial problem-solving skills were linked to long-term improvements in attention. Meanwhile, verbal intelligence scores were associated with long-term reductions in hyperactivity and impulsivity. The study also found that older participants tended to see better improvements in impulsivity, while younger participants saw greater gains in attention.

The study evaluated a specific demographic group, which shapes how the results apply to the broader population. The researchers exclusively enrolled adult men to limit potential biological variables in a related brain imaging analysis. As a result, the findings require validation in women and people of other genders to confirm whether the predictive tests work universally.

Additionally, the participants had no co-occurring mental health or developmental conditions, such as autism. People with ADHD frequently have other diagnoses, which can alter how they respond to stimulant medications. Testing these predictive models in a more diverse patient group will help determine their utility in everyday medical settings.

The models also need to be tested on entirely separate groups of patients. While the machine learning algorithms performed well on the data they were trained on, predictive tools often require external validation to ensure they do not just reflect the specific characteristics of the original sample.

The single-dose prediction approach remains in the testing phase and is not yet a replacement for standard clinical monitoring. In the future, researchers hope to incorporate physiological measures, such as heart rate variability, to build even more accurate predictive profiles. Combining objective computer tests, questionnaires, and biological markers could eventually help doctors tailor prescriptions to individual patients from day one.

The study, “Clinical response to a single-dose methylphenidate challenge is indicative of treatment response at two months in adults with ADHD,” was authored by Valeria Parlatini, Joaquim Radua, Hannah Thomas, Miguel Garcia-Argibay, Alessio Bellato, Samuele Cortese, and Declan Murphy.

URL: https://www.psypost.org/predictive-single-dose-test-could-guide-adhd-treatment-in-adults/

-------------------------------------------------

Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org

Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot

-------------------------------------------------

#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #ADHD #methylphenidate #single-doseprediction #adult ADHD #stimulantresponse #predictivepsychology #behavioralassessment #machinelearning #TranslationalPsychiatry #personalizedmedicine

DATE: August 6, 2026 at 12:00PM
SOURCE: PSYPOST.ORG

** Research quality varies widely from fantastic to small exploratory studies. Please check research methods when conclusions are very important to you. **
-------------------------------------------------

TITLE: ADHD medication helps children focus by stabilizing brain networks, new study suggests

URL: https://www.psypost.org/adhd-medication-helps-children-focus-by-stabilizing-brain-networks/

A small study shows that a common medication for attention deficit hyperactivity disorder helps children focus by stabilizing how different brain regions communicate with one another. The research, published in Translational Psychiatry, suggests that this brain stabilization is tied directly to better attention and task performance.

The brain constantly balances two opposing states, known as flexibility and stability. Flexibility allows a person to easily switch between different tasks or thoughts. Stability allows a person to ignore distractions and maintain focus on a single goal.

Children with attention deficit hyperactivity disorder, or ADHD, often struggle to maintain this balance. Their brain networks tend to change connections more rapidly. This frequent shifting can manifest as fluctuating attention, impulsive actions, and heightened sensitivity to rewards.

Foundational models of the disorder suggest that these symptoms arise from disruptions in specific neurological circuits. One circuit orients attention through executive control, while another tunes sensitivity to rewards through motivational control. Because these disruptions are widespread across multiple brain systems, looking at how the entire brain communicates is necessary to understand the condition.

Methylphenidate is a common first-line treatment for the disorder. The drug works by blocking the reuptake of dopamine and norepinephrine, which increases the levels of these chemical messengers in the brain. Dopamine and norepinephrine help regulate attention, executive control, and motivation.

The medication effectively reduces symptoms for many children, but up to 30 percent of patients do not experience improvements. A better understanding of how the drug alters brain function on a mechanical level is necessary to explain this variation in effectiveness.

Tehila Nugiel, a psychology researcher at Florida State University, led a team to investigate how methylphenidate influences the balance of brain flexibility and stability. The researchers suspected that the medication might reduce the rapid shifting of brain network connections, driving the brain into a more stable state.

Historically, researchers looked at brain connectivity by averaging activity over several minutes. Newer mathematical methods allow scientists to model how these networks reconfigure on a second-by-second basis. This high-resolution timeline is better suited for capturing the fleeting shifts in focus that characterize the disorder.

To test their hypothesis, the researchers designed a small study involving 31 children between the ages of 8 and 12 who had been diagnosed with ADHD. None of the participants had ever taken stimulant medication before.

Each child visited a laboratory for two separate brain scanning sessions, spaced about a week apart. One hour before entering the magnetic resonance imaging, or MRI, scanner, the children received either a single dose of methylphenidate or a placebo pill. Neither the researchers nor the children knew which pill was given on which day.

Inside the scanner, the children completed a standard test of sustained attention and impulse control. They viewed a series of sports balls on a screen and were instructed to press a button for certain balls and withhold their press for others. This tests a person’s ability to maintain focus without any external incentives.

After the standard version, the children completed a rewarded version of the same task. In this round, they saw feedback after each image, earning pennies for fast, correct responses and for correctly withholding a button press. The rewarded task tests how the brain adapts when performance is tied to an immediate, tangible benefit.

While the children completed these tasks, the researchers recorded their brain activity. Functional MRI tracks blood oxygen changes in the brain, allowing scientists to see which areas are communicating at any given moment. The researchers calculated whole brain flexibility, which measures how frequently different regions of the brain change their functional connections over short timescales.

The researchers also tracked behavioral performance during the scanning sessions. They measured response time variability, which indicates fluctuations in attention, and overall task accuracy.

When the children took methylphenidate, their whole brain flexibility decreased during both tasks. The connection patterns between different brain regions became more stable and persisted for longer periods of time.

This stabilization in the brain matched improvements in behavior. On the medication, the children displayed steadier attention, meaning their response times were less erratic on both tasks. They also achieved higher overall accuracy during the rewarded task.

To understand how the drug affected each child personally, the researchers compared the change in brain activity to the change in test scores. They found a direct relationship between the neural changes and the behavioral improvements. The individuals who experienced the largest decreases in brain flexibility on the medication also showed the greatest improvements in steady attention and accuracy.

These findings provide a biological explanation for how the medication aids cognition. By stabilizing whole brain network dynamics, the drug appears to reduce the neurological noise that often disrupts focus.

There are a few caveats to consider regarding the study design. The experiment involved a single dose of medication given to children who had never taken stimulants. Chronic use of the drug over months or years might alter brain network dynamics differently than an acute dose.

Additionally, the tests performed inside an MRI scanner isolate very specific cognitive processes. These controlled tasks do not perfectly mimic the complicated, distracting environments that children navigate in their daily lives.

The results also highlight notable individual differences among the participants. While the medication stabilized the brain and improved performance for most of the children, a small subset experienced the opposite effect. For these children, the drug increased brain flexibility and led to poorer task performance.

This variation offers a potential clue as to why stimulants fail to reduce symptoms in some individuals. Future research involving larger groups of participants could help scientists predict which patients will benefit from the medication and which might respond better to alternative treatments.

The study, “Methylphenidate stabilizes dynamic brain network organization during tasks probing attention and reward processing in stimulant-naïve children with ADHD,” was authored by Tehila Nugiel, Nicholas D. Fogleman, Monica G. Lyons, Margaret A. Sheridan, and Jessica R. Cohen.

URL: https://www.psypost.org/adhd-medication-helps-children-focus-by-stabilizing-brain-networks/

-------------------------------------------------

Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org

Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot

-------------------------------------------------

#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #ADHD #Methylphenidate #BrainNetworks #AttentionFocus #Neuroscience # ADHDResearch #StimulantMedication #ExecutiveFunction #RewardProcessing #Neuroimaging

DATE: August 6, 2026 at 12:00PM
SOURCE: PSYPOST.ORG

** Research quality varies widely from fantastic to small exploratory studies. Please check research methods when conclusions are very important to you. **
-------------------------------------------------

TITLE: ADHD medication helps children focus by stabilizing brain networks, new study suggests

URL: https://www.psypost.org/adhd-medication-helps-children-focus-by-stabilizing-brain-networks/

A small study shows that a common medication for attention deficit hyperactivity disorder helps children focus by stabilizing how different brain regions communicate with one another. The research, published in Translational Psychiatry, suggests that this brain stabilization is tied directly to better attention and task performance.

The brain constantly balances two opposing states, known as flexibility and stability. Flexibility allows a person to easily switch between different tasks or thoughts. Stability allows a person to ignore distractions and maintain focus on a single goal.

Children with attention deficit hyperactivity disorder, or ADHD, often struggle to maintain this balance. Their brain networks tend to change connections more rapidly. This frequent shifting can manifest as fluctuating attention, impulsive actions, and heightened sensitivity to rewards.

Foundational models of the disorder suggest that these symptoms arise from disruptions in specific neurological circuits. One circuit orients attention through executive control, while another tunes sensitivity to rewards through motivational control. Because these disruptions are widespread across multiple brain systems, looking at how the entire brain communicates is necessary to understand the condition.

Methylphenidate is a common first-line treatment for the disorder. The drug works by blocking the reuptake of dopamine and norepinephrine, which increases the levels of these chemical messengers in the brain. Dopamine and norepinephrine help regulate attention, executive control, and motivation.

The medication effectively reduces symptoms for many children, but up to 30 percent of patients do not experience improvements. A better understanding of how the drug alters brain function on a mechanical level is necessary to explain this variation in effectiveness.

Tehila Nugiel, a psychology researcher at Florida State University, led a team to investigate how methylphenidate influences the balance of brain flexibility and stability. The researchers suspected that the medication might reduce the rapid shifting of brain network connections, driving the brain into a more stable state.

Historically, researchers looked at brain connectivity by averaging activity over several minutes. Newer mathematical methods allow scientists to model how these networks reconfigure on a second-by-second basis. This high-resolution timeline is better suited for capturing the fleeting shifts in focus that characterize the disorder.

To test their hypothesis, the researchers designed a small study involving 31 children between the ages of 8 and 12 who had been diagnosed with ADHD. None of the participants had ever taken stimulant medication before.

Each child visited a laboratory for two separate brain scanning sessions, spaced about a week apart. One hour before entering the magnetic resonance imaging, or MRI, scanner, the children received either a single dose of methylphenidate or a placebo pill. Neither the researchers nor the children knew which pill was given on which day.

Inside the scanner, the children completed a standard test of sustained attention and impulse control. They viewed a series of sports balls on a screen and were instructed to press a button for certain balls and withhold their press for others. This tests a person’s ability to maintain focus without any external incentives.

After the standard version, the children completed a rewarded version of the same task. In this round, they saw feedback after each image, earning pennies for fast, correct responses and for correctly withholding a button press. The rewarded task tests how the brain adapts when performance is tied to an immediate, tangible benefit.

While the children completed these tasks, the researchers recorded their brain activity. Functional MRI tracks blood oxygen changes in the brain, allowing scientists to see which areas are communicating at any given moment. The researchers calculated whole brain flexibility, which measures how frequently different regions of the brain change their functional connections over short timescales.

The researchers also tracked behavioral performance during the scanning sessions. They measured response time variability, which indicates fluctuations in attention, and overall task accuracy.

When the children took methylphenidate, their whole brain flexibility decreased during both tasks. The connection patterns between different brain regions became more stable and persisted for longer periods of time.

This stabilization in the brain matched improvements in behavior. On the medication, the children displayed steadier attention, meaning their response times were less erratic on both tasks. They also achieved higher overall accuracy during the rewarded task.

To understand how the drug affected each child personally, the researchers compared the change in brain activity to the change in test scores. They found a direct relationship between the neural changes and the behavioral improvements. The individuals who experienced the largest decreases in brain flexibility on the medication also showed the greatest improvements in steady attention and accuracy.

These findings provide a biological explanation for how the medication aids cognition. By stabilizing whole brain network dynamics, the drug appears to reduce the neurological noise that often disrupts focus.

There are a few caveats to consider regarding the study design. The experiment involved a single dose of medication given to children who had never taken stimulants. Chronic use of the drug over months or years might alter brain network dynamics differently than an acute dose.

Additionally, the tests performed inside an MRI scanner isolate very specific cognitive processes. These controlled tasks do not perfectly mimic the complicated, distracting environments that children navigate in their daily lives.

The results also highlight notable individual differences among the participants. While the medication stabilized the brain and improved performance for most of the children, a small subset experienced the opposite effect. For these children, the drug increased brain flexibility and led to poorer task performance.

This variation offers a potential clue as to why stimulants fail to reduce symptoms in some individuals. Future research involving larger groups of participants could help scientists predict which patients will benefit from the medication and which might respond better to alternative treatments.

The study, “Methylphenidate stabilizes dynamic brain network organization during tasks probing attention and reward processing in stimulant-naïve children with ADHD,” was authored by Tehila Nugiel, Nicholas D. Fogleman, Monica G. Lyons, Margaret A. Sheridan, and Jessica R. Cohen.

URL: https://www.psypost.org/adhd-medication-helps-children-focus-by-stabilizing-brain-networks/

-------------------------------------------------

Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org

Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot

-------------------------------------------------

#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #ADHD #Methylphenidate #BrainNetworks #AttentionFocus #Neuroscience # ADHDResearch #StimulantMedication #ExecutiveFunction #RewardProcessing #Neuroimaging

Common #ADHD medication linked to increased frontal brain volume in children

»… found that higher cumulative doses of #methylphenidate were associated with increased gray matter volume in several frontal regions of the brain. However, this association was observed only in participants who began treatment before the age of 12 and was absent in those who started later.«

https://www.psypost.org/common-adhd-medication-linked-to-increased-frontal-brain-volume-in-children/

#ADHS

Common #ADHD medication linked to increased frontal brain volume in children

»… found that higher cumulative doses of #methylphenidate were associated with increased gray matter volume in several frontal regions of the brain. However, this association was observed only in participants who began treatment before the age of 12 and was absent in those who started later.«

https://www.psypost.org/common-adhd-medication-linked-to-increased-frontal-brain-volume-in-children/

#ADHS

Bollocks.
Woke up at 8am. Thought I'd just have another half hour before taking my #ADHD meds (which are a stimulant and therefore wake me up).
Woke up again at midday. Far too late to take my ADHD meds because they last 12+ hours.
#AuDHD #Neurospicy #Methylphenidate

Bollocks.
Woke up at 8am. Thought I'd just have another half hour before taking my #ADHD meds (which are a stimulant and therefore wake me up).
Woke up again at midday. Far too late to take my ADHD meds because they last 12+ hours.
#AuDHD #Neurospicy #Methylphenidate

Ça marche pas la Ritaline.
Il faut plusieurs jours pour voir les effets ?
Pour l'instant je ressens aucune différence.

#TDAH #TDA #Psychiatrie #psy #SanteMentale #Ritaline #methylphenidate

Ça marche pas la Ritaline.
Il faut plusieurs jours pour voir les effets ?
Pour l'instant je ressens aucune différence.

#TDAH #TDA #Psychiatrie #psy #SanteMentale #Ritaline #methylphenidate

I wish the medication shortage had been more of an election issue. Lots of people are struggling to get their scripts filled for a variety of conditions.

My son is doing well academically and emotionally right now, but every month I dread going to the pharmacy to be told they're out of his Concerta. Last month it was three chemists before I got some - the last one they had.

Why doesn’t Australia make more medicines? Wouldn’t that fix drug shortages?
https://theconversation.com/why-doesnt-australia-make-more-medicines-wouldnt-that-fix-drug-shortages-255766

#auspol #Medication #ADHD #Concerta #Ritalin #methylphenidate #TheConversationAU

I wish the medication shortage had been more of an election issue. Lots of people are struggling to get their scripts filled for a variety of conditions.

My son is doing well academically and emotionally right now, but every month I dread going to the pharmacy to be told they're out of his Concerta. Last month it was three chemists before I got some - the last one they had.

Why doesn’t Australia make more medicines? Wouldn’t that fix drug shortages?
https://theconversation.com/why-doesnt-australia-make-more-medicines-wouldnt-that-fix-drug-shortages-255766

#auspol #Medication #ADHD #Concerta #Ritalin #methylphenidate #TheConversationAU

Vous saurez plus que moi parce que vous savez tout.

j'ai du mal à dormir quand je prends 40 mg LP de Ritaline, je test 30mg voir si j'arrive à me coucher plus tôt.
Vous sauriez si y'a un moyen de couper cette énergie le soir ? je peux pas enchainer les jours comme ça :/

#methylphenidate #ritaline

Vous saurez plus que moi parce que vous savez tout.

j'ai du mal à dormir quand je prends 40 mg LP de Ritaline, je test 30mg voir si j'arrive à me coucher plus tôt.
Vous sauriez si y'a un moyen de couper cette énergie le soir ? je peux pas enchainer les jours comme ça :/

#methylphenidate #ritaline

Ritalin on the road: ADHD drug methylphenidate improves driving performance https://www.psypost.org/ritalin-on-the-road-adhd-drug-methylphenidate-improves-driving-performance/?utm_source=dlvr.it&utm_medium=mastodon #Ritalin #ADHD #Methylphenidate #DrivingPerformance #MentalHealth

Anyone out there using #ADHD meds like
#lisdexamfetamine / #lisdeksamfetamin ?

Typically aka #Vyvanse #Aduanz #Elvanse #Volidax #Balidax etc

...but you need a higher dosage compared to what's recommended?

The thing is, my previous Doc (and also ADHD expert) allowed me to exceed the recommended max dose (80mg/day) while testing #Ritalin (#methylphenidate / #metylfenidat) to find what actually worked for me.

(1/2)

Anyone out there using #ADHD meds like
#lisdexamfetamine / #lisdeksamfetamin ?

Typically aka #Vyvanse #Aduanz #Elvanse #Volidax #Balidax etc

...but you need a higher dosage compared to what's recommended?

The thing is, my previous Doc (and also ADHD expert) allowed me to exceed the recommended max dose (80mg/day) while testing #Ritalin (#methylphenidate / #metylfenidat) to find what actually worked for me.

(1/2)

Big day today, as I got my first ever ADHD prescription filled. The pharmacist heaved a pretty big sigh when he read it 😅

#ADHD
#methylphenidate

Day 3 of taking #Methylphenidate for my late-diagnosed ADD.

Starting off at 8:45. Today is probably the peak of multitasking as I work across different projects and jobs. A good field to notice changes. No unrealistically relaxed scenario. Instead, usual daily business.

This thread will be again followers-only for a good balance between privacy and openness. So, follow along if you are interested in #ADD / #ADHD struggles and attempts to tame the neuro-beast.

🧵1/10

Day 3 of taking #Methylphenidate for my late-diagnosed ADD.

Starting off at 8:45. Today is probably the peak of multitasking as I work across different projects and jobs. A good field to notice changes. No unrealistically relaxed scenario. Instead, usual daily business.

This thread will be again followers-only for a good balance between privacy and openness. So, follow along if you are interested in #ADD / #ADHD struggles and attempts to tame the neuro-beast.

🧵1/10

Day 2 of #Methylphenidate 10mg for my late-diagnosed adult ADD.

Falling asleep was hard. I woke up early and almost immediately felt a lack of motivation. I froze on the couch chaotically contemplating all the stuff I have to do. I feel overwhelmed.

After beakfast and coffee I am taking today's pill.

Follow along this thread, if you are interested.

Thread is followers only.

1/6

#ADHD #ADD

Day 2 of #Methylphenidate 10mg for my late-diagnosed adult ADD.

Falling asleep was hard. I woke up early and almost immediately felt a lack of motivation. I froze on the couch chaotically contemplating all the stuff I have to do. I feel overwhelmed.

After beakfast and coffee I am taking today's pill.

Follow along this thread, if you are interested.

Thread is followers only.

1/6

#ADHD #ADD

This style of chart is known as a “Pharmacokinetic diagram” and I’ve had to do a small amount of pharmacology research in order to generate it. I’ve validated it with friends and family who are more qualified than I in these fields.

I am very very aware that this is an approximation. Bodies are strange and don’t always do what the theory says, and error bars exist for a reason. I’ve built some approximations into the chart, and the rough estimate works for my purposes.

I am somewhat aided by the fact that #Methylphenidate is a drug that has very stable curves, very few things affect its uptake and elimination, mainly dosing alongside fatty foods. Caffeine has a similar effect, but modelling it would be much more difficult, as that first slope can be as short as 15 mins and as long as 90 depending on so many factors. #Stimgauge #ActuallyADHD

This style of chart is known as a “Pharmacokinetic diagram” and I’ve had to do a small amount of pharmacology research in order to generate it. I’ve validated it with friends and family who are more qualified than I in these fields.

I am very very aware that this is an approximation. Bodies are strange and don’t always do what the theory says, and error bars exist for a reason. I’ve built some approximations into the chart, and the rough estimate works for my purposes.

I am somewhat aided by the fact that #Methylphenidate is a drug that has very stable curves, very few things affect its uptake and elimination, mainly dosing alongside fatty foods. Caffeine has a similar effect, but modelling it would be much more difficult, as that first slope can be as short as 15 mins and as long as 90 depending on so many factors. #Stimgauge #ActuallyADHD

Fuck. Fucking DEA. Finally got me.

Yeah it’s methylphenidate. The shortage. Or, “shortage”, because the DEA limits how much methylphenidate pharmaceutical firms are able to bring to market, and they don’t care if their limits are sufficient to meet demand.

#methylphenidate #ritalin #adhd #shortage

I took my #ritalin too late and now I am not getting tired. If I go to bed when I finally will get tired, I would certainly oversleep tomorrow...

So, I think I’ll pull an #allnighter. 🎉☕😑

#adhd #methylphenidate

@unfortunateshort @thor It depends very much on the meds. I’m a big fan of #methylphenidate (#Ritalin). Available for over 50 years, no addiction, it works from day 1, no tapering, and limited side effects. It also replaces an #ADHD test: if you feel like on cocaine, you don’t have ADHD. 😅

Disclaimer:
Just in case someone without a sense of humour reads this Toot, I’d like to stress that the last point was a joke. I STRONGLY advise against taking this stuff without medical supervision!

So today my psychiatrist decided that I should switch my #ADHD meds from #methylphenidate to #lisdexamfetamine

I had just gotten to a dose that was working almost well enough, the side effects were abating, and I was just happy that I was getting maybe 4 or 5 functional hours a day.

But I described to him that I have started getting extremely tired around 16 in the afternoon, when the drug starts to wear off, and that is when he suggested that I switch. I think he both thought that 4-5 hours is not good enough, and also that the tiredness is unacceptable.

So now I'm both excited to see how lisdexamfetamine is going to work out, but I'm also really afraid, because the last few months on methylphenidate has been the first time in years, that I have been able to function, and I'm afraid to lose that.

It is such a fragile balance between being able to fall asleep at night, and actually staying asleep all night, and then having the ADHD meds be effective, but not so much that they interfere with the sleep.

Any #adhd people on #methylphenidate out there that have appetite suppression issues after tasking meds? Can you describe it to me please? I think that's what happening but don't know how to describe it

Any #adhd people on #methylphenidate out there that have appetite suppression issues after tasking meds? Can you describe it to me please? I think that's what happening but don't know how to describe it

The effects of methylphenidate (Ritalin) so far... Palpitations, zombie like disassociation, extreme anxiety, a sense of calm and wellbeing, stronger than usual feelings of love and affection, complete lack of interest in food, extreme hunger, alertness and sleeplessness, overwhelming tiredness and sleepiness...

Essentially it seems to be taking the normal feelings and experience of having two small children and ADHD and turning everything up to 11...

#ADHD
#actuallyadhd
#methylphenidate

The effects of methylphenidate (Ritalin) so far... Palpitations, zombie like disassociation, extreme anxiety, a sense of calm and wellbeing, stronger than usual feelings of love and affection, complete lack of interest in food, extreme hunger, alertness and sleeplessness, overwhelming tiredness and sleepiness...

Essentially it seems to be taking the normal feelings and experience of having two small children and ADHD and turning everything up to 11...

#ADHD
#actuallyadhd
#methylphenidate

Heads up that the Adderall shortage has wandered over to the Concerta/Ritalin/Methylphenidate side of the fence. It may depend on your dose and whether it’s extended release. But my pharmacy’s provider has no idea when they will have more 36mg ER in. Not sure about 54 (which I was just going to see if I could move to).

#adhd #ritalin #methylphenidate #concerta